EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models.

Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, Patel RP, Tan M, Padmanabhan AA, Lemoine J, Fardella E, Zhang Y, Pajarillo R, Chen L, Ugwuanyi O, Markowitz K, Delman D, Angelos MG, Shestova O, Isshiki Y, Blanchard T, Béguelin W, Melnick AM, Linette GP, Beatty GL, Carreno BM, Cohen I, Paruzzo L, Schuster SJ, Ruella M. Cancer Cell. 2025 Feb 20:S1535-6108(25)00031-5. doi: 10.1016/j.ccell.2025.01.013. Online ahead of print. PMID: 39983725